Rhonda E. Ries

9.1k total citations
105 papers, 1.0k citations indexed

About

Rhonda E. Ries is a scholar working on Hematology, Molecular Biology and Cancer Research. According to data from OpenAlex, Rhonda E. Ries has authored 105 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Hematology, 65 papers in Molecular Biology and 31 papers in Cancer Research. Recurrent topics in Rhonda E. Ries's work include Acute Myeloid Leukemia Research (89 papers), Protein Degradation and Inhibitors (31 papers) and Cancer Genomics and Diagnostics (25 papers). Rhonda E. Ries is often cited by papers focused on Acute Myeloid Leukemia Research (89 papers), Protein Degradation and Inhibitors (31 papers) and Cancer Genomics and Diagnostics (25 papers). Rhonda E. Ries collaborates with scholars based in United States, Canada and Switzerland. Rhonda E. Ries's co-authors include Soheil Meshinchi, Todd A. Alonzo, Alan S. Gamis, Richard Aplenc, Betsy Hirsch, Robert B. Gerbing, Susana C. Raimondi, Michael R. Loken, Roland B. Walter and E. Anders Kolb and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Rhonda E. Ries

95 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rhonda E. Ries United States 16 652 605 184 183 174 105 1.0k
Ann‐Kathrin Eisfeld United States 19 563 0.9× 519 0.9× 133 0.7× 303 1.7× 145 0.8× 64 1.0k
Phoenix A. Ho United States 15 876 1.3× 550 0.9× 259 1.4× 176 1.0× 351 2.0× 29 1.2k
Cornelia Schlee Germany 17 455 0.7× 497 0.8× 131 0.7× 181 1.0× 403 2.3× 27 960
Brian Ball United States 14 576 0.9× 625 1.0× 141 0.8× 114 0.6× 70 0.4× 45 1.0k
Maria‐Cristina Sauerland Germany 8 1.1k 1.6× 688 1.1× 150 0.8× 147 0.8× 294 1.7× 10 1.2k
Ellen Geerdens Belgium 16 315 0.5× 438 0.7× 216 1.2× 146 0.8× 337 1.9× 17 970
Olga Sala‐Torra United States 12 378 0.6× 233 0.4× 160 0.9× 66 0.4× 168 1.0× 31 707
Heinz-A. Horst Germany 6 443 0.7× 360 0.6× 163 0.9× 230 1.3× 135 0.8× 6 791
Lars Klemm United States 11 220 0.3× 425 0.7× 189 1.0× 76 0.4× 246 1.4× 34 818
Olga Salamero Spain 13 625 1.0× 381 0.6× 167 0.9× 49 0.3× 180 1.0× 46 890

Countries citing papers authored by Rhonda E. Ries

Since Specialization
Citations

This map shows the geographic impact of Rhonda E. Ries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhonda E. Ries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhonda E. Ries more than expected).

Fields of papers citing papers by Rhonda E. Ries

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhonda E. Ries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhonda E. Ries. The network helps show where Rhonda E. Ries may publish in the future.

Co-authorship network of co-authors of Rhonda E. Ries

This figure shows the co-authorship network connecting the top 25 collaborators of Rhonda E. Ries. A scholar is included among the top collaborators of Rhonda E. Ries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rhonda E. Ries. Rhonda E. Ries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Aifen, Adam J. Lamble, Rhonda E. Ries, et al.. (2025). TP53 inactivation confers resistance to the menin inhibitor revumenib in Acute Myeloid Leukemia. Blood. 146(Supplement 1). 3470–3470.
2.
3.
Abla, Oussama, Rhonda E. Ries, Timothy J. Triche, et al.. (2024). Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Advances. 8(8). 2005–2017. 1 indexed citations
4.
Farrar, Jason E., Jenny L. Smith, Megan Othus, et al.. (2023). Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology. 41(16). 2949–2962. 13 indexed citations
5.
Bolouri, Hamid, Rhonda E. Ries, Alice Wiedeman, et al.. (2022). Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes. Nature Communications. 13(1). 7186–7186. 3 indexed citations
6.
Choudhury, Samrat Roy, Jordan T. Bird, Stephanie D. Byrum, et al.. (2021). Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors. Blood. 138(Supplement 1). 2208–2208. 2 indexed citations
7.
Srivastava, Shivani, Jenny L. Smith, Amanda R. Leonti, et al.. (2021). Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clinical Cancer Research. 27(20). 5718–5730. 17 indexed citations
8.
Bolouri, Hamid, Rhonda E. Ries, Laura Pardo, et al.. (2021). A B-cell developmental gene regulatory network is activated in infant AML. PLoS ONE. 16(11). e0259197–e0259197. 7 indexed citations
9.
Wei, Lisa L., Diane L. Trinh, Rhonda E. Ries, et al.. (2020). Integrative Analysis of Single-Cell RNA-Seq and ATAC-Seq Data across Treatment Time Points in Pediatric AML. Blood. 136(Supplement 1). 29–29. 2 indexed citations
10.
Tarlock, Katherine, Todd A. Alonzo, Yi-Cheng Wang, et al.. (2019). Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clinical Cancer Research. 25(16). 5038–5048. 39 indexed citations
11.
Hagiwara, Kohei, Liang Ding, Michael N. Edmonson, et al.. (2019). RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics. 36(5). 1382–1390. 11 indexed citations
12.
Tarlock, Katherine, Todd A. Alonzo, Michael R. Loken, et al.. (2017). Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 23(14). 3649–3656. 20 indexed citations
13.
Cooper, Todd M., Rhonda E. Ries, Todd A. Alonzo, et al.. (2017). Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood. 130. 407–407. 10 indexed citations
14.
Kaeding, Allison, Katherine Tarlock, Sonali P. Barwe, et al.. (2017). Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia. Blood. 130. 2641–2641. 1 indexed citations
15.
Fan, Yu, Ying Hu, Cu Nguyen, et al.. (2017). Altered Transcriptome Uniquely Associated with AML Vs. Normal Hematopoiesis. Blood. 130. 3792–3792. 1 indexed citations
16.
Farrar, Jason E., Rhonda E. Ries, Daniel Wai, et al.. (2016). Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Research. 76(8). 2197–2205. 104 indexed citations
17.
Biernacki, Melinda A., et al.. (2016). Identifying Leukemia-Specific Neoepitopes from Next-Generation Sequencing Data to Develop Targeted Immunotherapy for Pediatric Acute Myeloid Leukemiaig. Biology of Blood and Marrow Transplantation. 22(3). S19–S19. 1 indexed citations
18.
19.
Laszlo, George S., Todd A. Alonzo, Chelsea J. Gudgeon, et al.. (2015). Multimerin-1 ( MMRN1 ) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 21(14). 3187–3195. 20 indexed citations
20.
Dvinge, Heidi, Rhonda E. Ries, Janine O. Ilagan, et al.. (2014). Sample processing obscures cancer-specific alterations in leukemic transcriptomes. Proceedings of the National Academy of Sciences. 111(47). 16802–16807. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann‐Kathrin Eisfeld Breakdown of academic impact, for papers by Phoenix A. Ho Breakdown of academic impact, for papers by Cornelia Schlee Breakdown of academic impact, for papers by Brian Ball Breakdown of academic impact, for papers by Maria‐Cristina Sauerland Breakdown of academic impact, for papers by Ellen Geerdens Breakdown of academic impact, for papers by Olga Sala‐Torra Breakdown of academic impact, for papers by Heinz-A. Horst Breakdown of academic impact, for papers by Lars Klemm Breakdown of academic impact, for papers by Olga Salamero
Rankless by CCL
2026